Financials data is unavailable for this security.
View more
Year on year Tianda Pharmaceuticals Ltd grew revenues 29.77% from 410.02m to 532.09m while net income improved from a loss of 40.98m to a smaller loss of 24.16m.
Gross margin | 45.83% |
---|---|
Net profit margin | -12.30% |
Operating margin | -10.51% |
Return on assets | -5.34% |
---|---|
Return on equity | -8.25% |
Return on investment | -7.97% |
More ▼
Cash flow in HKDView more
In 2023, cash reserves at Tianda Pharmaceuticals Ltd fell by 177.84m. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 49.76m. In addition the company used 69.10m on investing activities and also paid 57.39m in financing cash flows.
Cash flow per share | -0.0046 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.2533 |
---|---|
Tangible book value per share | 0.194 |
More ▼
Balance sheet in HKDView more
Current ratio | 0.9642 |
---|---|
Quick ratio | 0.6748 |
Total debt/total equity | 0.1815 |
---|---|
Total debt/total capital | 0.1536 |
More ▼
Growth rates in HKD
Growth rate information is not available.
Div yield(5 year avg) | 0.88% |
---|---|
Div growth rate (5 year) | -- |
Payout ratio (TTM) | -- |
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | -- |
More ▼